Microgravity at Scale: Turning Insight into Impact

Why does glioblastoma often return after treatment? Joe Costello, Ph.D., of UC San Francisco, examines two connected processes underlying this aggressive brain cancer: tumor evolution and the ability of cancer cells to keep dividing. Using three-dimensional sampling across multiple regions of brain tumors, his research investigates small populations of early ancestral cells that appear to survive treatment and may contribute to recurrence. Costello also examines how changes involving the TERT gene help tumor cells maintain their ability to divide. In laboratory and animal experiments, his team tests ways to interfere with proteins that activate TERT, while using artificial intelligence to identify additional potential targets. Although much of this research remains preliminary, it offers new insights into why glioblastoma is difficult to treat and possible directions for future therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40859]

Blood-forming stem cells replenish the blood and immune system, making them important targets for gene therapy and transplantation. Cynthia Dunbar, M.D., explains how genetic barcodes let scientists track individual stem cell clones over time. Long-term studies in nonhuman primates reveal stable contributions from blood stem cells and unexpected persistence among certain natural killer immune cells. Dunbar reviews successes and safety concerns in gene therapy, including leukemias associated with some integrating viral vectors. She compares these approaches with CRISPR gene editing, examining challenges in precise gene insertion, stem cell recovery after transplantation, and age-related clonal hematopoiesis. She also addresses treatment costs, intensive preparation for transplantation, and barriers to patient access. These insights help researchers evaluate new treatments more carefully and work toward safer, more accessible care. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40858]

Heart repair is moving beyond a single strategy. Catriona Jamieson, M.D., Ph.D., Ehtisham Mahmud, M.D., FACC, FSCAI, Eric Adler, M.D., Karen Christman, Ph.D., and set designer Robert Brill discuss approaches to preventing and repairing heart damage. Mahmud describes a model linking cardiovascular care, training and clinical research. Adler explains how patient skin cells can be turned into beating heart cells to study genetic cardiomyopathies and develop targeted therapies. Christman discusses injectable extracellular matrix materials designed to reduce inflammation, limit scar formation and support repair after a heart attack. Brill connects the science to The Heart, a theatrical work shaped by medicine, organ donation and community. Together, the discussion shows how collaboration across medicine, bioengineering and the arts can expand approaches to heart disease and healing. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41544]

Heart regeneration faces two connected challenges: replacing lost muscle and keeping transplanted cells safe and accepted by the body. Charles Murry, M.D., Ph.D., of USC explains why the adult heart heals major cardiomyocyte loss with scar tissue rather than new muscle, leading to progressive heart failure. Murry describes how stem cell derived cardiomyocytes can be manufactured at scale, transplanted into injured hearts, and tested for function in animal models. He also examines major barriers, including graft related arrhythmias, calcium handling stress, immune rejection, and the need for practical immunosuppression or immune edited cells. By connecting cell manufacturing, electrophysiology, immunology, and clinical trial planning, this research shows why heart regeneration is difficult and why careful translation matters for patients with severe heart injury. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40853]

Hematopoietic stem cells make blood across the lifespan, but they do not all behave the same way. Stephanie Xie, Ph.D., Scientist at Princess Margaret Cancer Centre, University of Toronto, examines how these rare cells self-renew, differentiate, and respond to inflammatory stress, asking whether differences in the stem cell pool help explain why aging affects people so differently. Xie identifies two hematopoietic stem cell subsets, including one that retains inflammatory memory after stress recovery, and connects this state to aging, clonal hematopoiesis, sickle cell disease, post-COVID recovery, and mortality risk markers in blood. Her research also raises questions about whether targeting the inflammatory environment, including through GLP-1 receptor agonists or metformin, could help mitigate clonal hematopoiesis. Understanding these patterns could clarify how inflammation shapes blood production, cancer risk, and immune health over time. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41406]

Rare disease research is creating new paths for diagnosis, treatment, and broader medical discovery. Gene therapy can repair or replace faulty genes, and work on cystinosis has led to a stem cell platform now being applied to Danon disease, Sanfilippo syndrome C, Friedreich’s ataxia, and Alzheimer’s research. Funding programs support gene therapy, clinical trials, and new platform approaches for rare diseases. CAR-T cell research is also advancing treatment possibilities for pediatric brain tumors, including early results in children with DIPG and diffuse midline glioma. A patient advocate shares her daughter’s diagnostic odyssey and treatment for TUBB4A leukodystrophy. Together, these stories show why rare disease research matters beyond rarity. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41402]

Pre-cancer and cancer can begin when stressed blood-forming stem cells lose their normal controls. Catriona Jamieson, M.D., Ph.D., UC San Diego, explains how inflammation-linked editing enzymes, repetitive elements in the genome, and stem cell stress shape the progression from myeloproliferative neoplasms to acute myeloid leukemia. Jamieson examines how spaceflight accelerates stem cell aging, how some astronauts mobilize a resilient regenerative stem cell population, and how tumor organoids in space help reveal drug responses by activating the enzyme ADAR1. This work helps explain how cancer starts, why it can return, and how space-based research may speed the development of therapies that stop malignant stem cells before disease advances. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41473]

Space healthcare depends on connected health data that can follow people wherever care happens. Peter DeVault, Epic, explains how electronic health record tools built for hospitals, labs, and patients can also support healthcare in space. DeVault describes patient-facing tools like MyChart, interoperability across health systems, structured genomics and pharmacogenomics in the patient record, and Cosmos, Epic’s patient data aggregation platform with about 300 million longitudinal records. He also examines AI capabilities that can generate possible future health scenarios and expand to telemetry and molecular data collected before, during, and after a mission. This work helps explain how records, data sharing, and predictive tools could support astronaut health and resilience and why those capabilities may be necessary for the future of space medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41481]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Microgravity can change biological systems in ways that may open new paths for biomedical research and commercialization in space. Twyman Clements, Space Tango, explains how “middleware” helps connect research use cases with space infrastructure by adapting terrestrial processes and supply chains for a spaceflight environment. Clements examines how long-duration microgravity creates different physical conditions, how Space Tango packages experiments into flight-ready lab systems, and how commercial space stations and reentry systems could help increase scale, throughput, and production value. He also points to more robotic systems that could support on-orbit sampling, imaging, and experiment assembly. This work helps explain how space-based biomedical research could move beyond small experimental missions and toward more practical, scalable platforms for discovery and development Series: "Stem Cell Channel" [Science] [Show ID: 41480]